TAT-cyclo-CLLFVY |
Catalog No.GC50211 |
TAT-cyclo-CLLFVY est un inhibiteur peptidique cyclique de l'hétérodimérisation de HIF-1 qui inhibe la signalisation de l'hypoxie dans les cellules cancéreuses. TAT-cyclo-CLLFVY perturbe l'interaction protéine-protéine HIF-1α/HIF-1β avec une IC50 de 1,3 μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1446322-66-2
Sample solution is provided at 25 µL, 10mM.
Selective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM). Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.
Miranda et al (2013) A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J.Am.Chem.Soc. 135 10418 PMID:23796364
Average Rating: 5
(Based on Reviews and 7 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *